SEC EDGAROCT 21 min read$MAZE

Coloma Jason V sold $932K of MAZE (indirect holdings)

Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $27.02 ($27.02–$27.02, $0.93M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Coloma Jason V

Published Oct 2, 2026, 8:12 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 2, 2026, 8:19 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MAZE

Bearish

medium confidence

Mentioned

$MAZE

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MAZEBearishLow

Why it matters

The disclosed sale may prompt short‑term price weakness, but the pre‑arranged nature tempers the signal.

Market read

Insider sale of nearly $1M by the CEO could modestly affect MAZE's share price in the short term.

What to watch

The 10b5‑1 plan indicates the sale was pre‑planned, reducing the informational weight.

Relevance 4/10Novelty 4/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; a CEO sale is closely watched by investors.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MAZEBearishMedium confidence

Context

CEO Jason V. Coloma sold $932K of MAZE shares via a 10b5‑1 plan, reducing his holdings to 191,447 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $932K sale by the CEO is material for a small‑cap biotech and can trigger short‑term selling.

Market effects

Sector

May raise concerns for other biotech stocks with recent insider sales.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine execution of a pre‑arranged plan, not a negative signal.

Key entities

person
Jason V. Coloma
Chief Executive Officer of Maze Therapeutics
company
Maze Therapeutics, Inc.
Biotech company developing epigenetic therapies, ticker MAZE

Read at source ← All news

OCT 19

$MAZEHigh

Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential

Canaccord Genuity initiated coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and $75.00 price target, citing its kidney disease treatment and pipeline. The stock has a $1.53B market cap and is down 33.55% YTD. Analysts highlight MZE829, an APOL1 inhibitor for kidney disease, and MZE782 for phenylketonuria and chronic kidney disease. Maze holds more cash than debt. Raymond James maintains a Strong Buy rating on MAZE and Market Perform on Vertex Pharmaceuticals (VRTX).

investing.com2 min

SEP 29

$VRTXHighAI 9/10

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

Truist analyst Danielle Brill highlighted a positive readthrough for Maze Therapeutics (MAZE) after Vertex Pharmaceuticals (VRTX) reported successful Phase 2 data for a kidney disease treatment. The data supports a large market opportunity, with Truist maintaining a Buy rating and $64 target for Maze. Vertex reported $3.33 billion in Q2 2026 revenue and raised its full-year 2026 guidance to $13.1–$13.2 billion.

insidermonkey.com2 min

SEP 23

$MAZEHigh

Why is Maze Therapeutics stock climbing today?

Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.

investing.com1 min

SEP 22

$VRTXMedAI 8/10

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.

newsable.asianetnews.com2 min

AUG 11

$MAZEMed

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongo

SEC EDGAR 8-K4 min